Bayer, Japanese university partner for Alzheimer's research

09/11/2008 | PipelineReview.com

Bayer Schering Pharma and the University of Nagasaki in Japan have signed a licensing agreement for the use of novel molecular imaging agents developed there as PET radiotracers to help in the early detection of Alzheimer's disease. The agreement grants Bayer exclusive worldwide rights to manufacture and sell a set of radiolabeled molecules.

View Full Article in:

PipelineReview.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA